H.C. Wainwright analyst Amit Dayal maintained a Buy rating on Marrone Bio (MBII) today and set a price target of $2.50. The company’s shares closed on Friday at $1.65.
Dayal wrote:
“We are projecting MBII to generate revenues of $28.6M in 2019. We continue to project revenues to reach over $150.0M in 2025, growing at a six-year CAGR of 32.4%, relative to 2019 levels. We are estimating gross margins of 47.4% during 2019 and expect these to approach 50.0% levels during the next several years.”
According to TipRanks.com, Dayal is ranked 0 out of 5 stars with an average return of -7.5% and a 42.9% success rate. Dayal covers the Industrial Goods sector, focusing on stocks such as Ballard Power Systems, Capstone Turbine Corp, and Orion Energy Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Marrone Bio with a $2.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.39 and a one-year low of $1.10. Currently, Marrone Bio has an average volume of 126.1K.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marrone Bio Innovations, Inc. engages in the provision of bio-based pest management and plant health products for the agricultural and water treatment markets. Its brand includes regalia, bio-tam, grandevo, venerate, and majestene. The company was founded by Pamela G. Marrone on June 15, 2006 and is headquartered in Davis, CA.
